Does Genomic Health Have Another Winner with Oncotype DX Prostate Cancer Test?

Oncotype DX definitely produced a winner with its Breast Cancer Assay. Here are the results of the test according to the company web site: 33% [of tested patients] switched from chemotherapy + hormone therapy to hormone therapy alone based on a low Recurrence Score result 4% [of tested patients] switched from hormonal therapy only to chemotherapy + hormonal therapy based on a high Recurrence Score result The company is now introducing a new assay for assessing the risk of biopsied prostate cancer (see: New Test Improves Assessment of Prostate Cancer Risk, Study Says). Here's an excerpt from a recent article discussing this new test: A new test can help distinguish aggressive prostate cancer from less threatening ones, potentially saving many men from unneeded operations for tumors that would never hurt them, researchers are reporting....Results of a study assessing the test’s performance will be presented...at the annual meeting of the American Urological Association in San Diego....Still, some experts said it was too early to assess how accurate the test [developed by Genomic Health] really was and whether it would make a difference in men’s decisions. Insurers are going to want to know that before deciding to pay for the test...at a list price of $3,820....The new test, which is called the Oncotype DX Prostate Cancer Test, is one of more than a dozen coming to market that use advanced genetic methods to help better manage prostate cancer......
Source: Lab Soft News - Category: Pathologists Authors: Tags: Clinical Lab Industry News Clinical Lab Testing Healthcare Business Laboratory Industry Trends Medical Research Surgical Pathology Source Type: blogs